Myeloma Canada Board of Directors
Myeloma Canada is governed by a Board of Directors whose role is to provide leadership, guide the strategic direction of the organization, and ensure that it achieves its mission. Central to this, is the reinforcement and development of our four pillars: Education, Awareness, Access & Advocacy, and Science & Research.
Johanne Mullen, Chair
Johanne Mullen is a partner in the Deals Practice of PricewaterhouseCoopers LLP. She specializes in project financing and public-private partnerships (PPPs), and provides advice to clients with respect to the development and financing of large projects, notably in the infrastructure sector. Her advisory experience includes developing business cases, developing financing and funding strategies, securing credit ratings, running competitions to identify financiers, as well as implementing, negotiating, and closing financings.
Some of Johanne’s recent mandates include McGill University Health Centre’s $1.3 billion redeployment to the Glen campus; Centre hospitalier universitaire de Québec’s redevelopment of the Hôtel Dieu Hospital; the cities of Longueuil and Montreal water infrastructure funding; and city of Montreal’s transportation infrastructure funding.
Johanne is regularly invited to speak at conferences on the subjects of PPPs and project financing. She is also president of the “Institut pour le partenariat public privé du Québec” (Institute for public private partnerships of Quebec).
Johanne holds a Bachelor of Commerce in Finance from Concordia University and a Master of Business Administration in International Business from McGill University.
Eric Low, Vice-Chair
Eric has worked in the fields of medical research, market access and patient organisations for over 25 years. He currently runs a consultancy business specializing primarily in strategic market access, life sciences and healthcare policy, and patient organization development.
Eric is committed to, and focused on, improving patient outcomes and puts patients at the center of everything he does. His career goal is to make a significant impact on both, the quality of life of patients, and on the prevention and curability of cancer and rare diseases. Eric has a strong track record of delivery and success in building multi-stakeholder research collaborations, patient coalitions, market access strategies and change policy. Moreover, Eric is skilled at providing innovative solutions to complex issues and challenges, as well as breaking down barriers to facilitate and ensure progress.
Additionally, Eric is a Senior Visiting Research fellow at the University of Leeds Medical School, and holds several other Board, honorary, advisory, and voluntary positions, including advising numerous medical and health-focused charities on a pro bono basis. Eric was awarded an OBE (Officer of the Most Excellent Order of the British Empire) for services to charity in the Queen’s Birthday Honours 2012.
Lorelei Dalrymple, Treasurer
Lorelei works as a Team Lead for Alberta's largest credit union. Since her 2009 diagnosis, she has been extremely active in the Canadian myeloma community, holding roles on the Myeloma Alberta Support Society Board, including President for three years, and Myeloma Canada's Patient Advisory Council where she has been Chair since 2016. Lorelei has been instrumental in Myeloma Canada's Support Group Leader and Advocacy Summits, the Myeloma Awareness Day at the Alberta legislature, and the Myeloma Canada Early Diagnosis program. She is a member of the Board of the Myeloma Canada Research Network and a steering committee member of Myeloma Canada's Myeloma Priority Setting Partnership for research in Canada. Lorelei is thrilled to join the Myeloma Canada Board and ensure the voices of myeloma patients are represented.
Antoinette Bozac, Secretary
Antoinette is an expert trustee and award-winning lawyer in Canada, as well as a Corporate Services Executive with over 20 years' experience at public, private and crown corporations in highly regulated industries, including healthcare. In addition to leading the compliance, governance, human resources and legal functions, Antoinette has experience in managing pensions and benefits, health and safety, insurance and risk management, operational strategy, corporate social responsibility and sustainability, government and investor relations, public affairs, and communications. She has extensive Board Director experience, including with health-focused charities. Antoinette is a Governor of Concordia University and the government-appointed Trustee for l'Association des enseignant(e)s francophones d'Ontario. She is fluently trilingual, Lean Six Sigma certified, and a synchronized skater. Antoinette is honoured to be joining the Board of Myeloma Canada.
Ellis Basevitz, Director
Ellis Basevitz joined Myeloma Canada’s Board of Directors, as treasurer. He is the founder of the accounting firm PSB Boisjoli.
Ellis owes his career success to his ability to establish lasting relationships with clients and business partners. Known for his enthusiasm for problem solving, he provides original and creative ideas that help clients save money and grow their assets. His services are based on mutual trust, knowing how to listen to and understand the needs and objectives of clients, and partnering with clients in the development of short and long-term strategies, whether personal or business.
During his career, Ellis has been a mentor and an example for many young accountants who have now become partners. He has shared with them his philosophy on customer service and trained them to provide value-added services.
Within the firm, Ellis is a consultant valued for his vision, creativity, and originality, and has assumed marketing and business development roles.
Ellis is a Quebec Chartered Accountant (CA). He is also a member of the Ordre des comptables agréés du Québec and of the Canadian Institute of Chartered Accountants.
Donna Reece, MD, Director
Donna Reece is Professor of Medicine at the University of Toronto and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. She holds the Molly and David Bloom Chair in Multiple Myeloma Research and is Chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, as well as a Co-Chair of the Myeloma Working Committee at the Center for International Blood and Marrow Transplant Research. She also serves on the Myeloma Canada Scientific Advisory Board and leads the Myeloma Canada Research Network.
Anthony Reiman, MD, Director
Anthony Reiman is a medical oncologist with a special interest in the study and treatment of myeloma. He is based at the Saint John Regional Hospital in New Brunswick and is a member of the Board of Directors of the New Brunswick Health Research Foundation and of the Beatrice Hunter Cancer Research Institute. He is the Canadian Cancer Society Research Chair at the University of New Brunswick and the Assistant Dean, Research, at Dalhousie Medicine, New Brunswick.
Anthony is currently a Professor of Medicine at Dalhousie University, and is an active researcher with over 100 publications in peer-reviewed journals. Anthony is also the co-chair of the myeloma committee at the Canadian Cancer Trials Group, and a member of both the US National Cancer Institute Myeloma Steering Committee and the International Myeloma Working Group. He sits on several committees with the Myeloma Canada Research Network.
Emily Crowe, PhD, Director
Emily specialises in health technology assessment (HTA) and evidence requirement and is a Senior Scientific Adviser in the Scientific Advice program at the National Institute for Health and Care Excellence (NICE) in the UK. Emily also leads the development of a parallel advice service with the Canadian Agency for Drugs and Technologies in Health. Additionally, she advises on clinical trial development programs and plans for health economic evaluation, preparing developers for evaluation by payers. Emily has a PhD in biochemistry from the University of British Columbia and completed postdoctoral research in immune cell biology. She works closely with patients to gain a deeper understanding of the unmet medical need for new treatments to improve survival and quality of life and as such, is very proud to be joining the Board of Myeloma Canada.
Mélanie Martel, Director
Mélanie is a partner at the law firm of DLA Piper where she practises in the areas of Commercial Litigation, Construction Law, Latent Defects, Class Actions, sale contracts, lease disputes, bankruptcy and insolvency. She represents a broad range of clients before all levels of the court, but also acts to prevent, avoid and settle litigation where possible. Mélanie has been teaching Contract Law (sale, lease, service and enterprise) at the University of Sherbrooke since 2008, as well as the Law of Obligations and Proceedings at the Quebec Bar School since 2009. She is active in the community and currently serves as Director of the Société de Transport de Laval. Serving on the Myeloma Canada Board represents both a personal and professional honour for Mélanie as her sister is currently fighting myeloma.
Keith Taylor, Director
Keith studied at the University of British Columbia, Cambridge University and Sheffield University. He has worked as a police officer in London, UK and with the Vancouver Police Department, as well as in research, planning and management with the Calgary Police Service, the Justice Institute of BC and Canada Post. He has served on several Boards and committees and is currently Partner in a consulting firm specializing in police, justice, governance and community issues. An accomplished photographer, he enjoys short-course triathlons, hiking and biking. Diagnosed with myeloma in 2012, Keith has been in remission since 2014. As a Director on Myeloma Canada's Board, he is grateful to give back to the myeloma community for what he describes as the superb care he receives as a patient.
Arleigh Robertson McCurdy, MD, Director
Arleigh is an assistant professor in the Faculty of Medicine at the University of Ottawa, Division of Hematology and Department of Medicine. She is the Lead of the Multiple Myeloma Program at The Ottawa Hospital and a Clinician Investigator at the Ottawa Hospital Research Institute in Ottawa, Ontario.
Alreigh holds a Masters of Health Administration degree from Dalhousie University and has a keen interest in health policy. Her clinical research is focused on multiple myeloma and related disorders. In addition, Arleigh is an active member of the Canadian Myeloma Research Group (CMRG) and the Canadian Cancer Trials Group, Myeloma Committee.
Hira Mian, MD, Director
Hira is a hematologist at the Juravinski Cancer Centre and an assistant professor within the department of oncology at McMaster University in Hamilton, Ontario, where she specializes in multiple myeloma. Hira completed her clinical training at the University of Toronto and furthered her research training at McMaster University where she obtained her Masters in Health Research Methodology, as well as completed the Royal College Accredited Clinician Investigator Program.
Hira’s research interests center around health services and outcomes, with a specific focus on disparities in access to care/outcomes and quality of life among patients with myeloma. She is also very involved in research activities with the Canadian Myeloma Research Group (CMRG), the Canadian Cancer Clinical Trials Group as well as the International Society of Geriatric Oncology.
Nancy Gray, Director
Nancy Gray is a chartered professional accountant who has worked in the fields of health and post-secondary education for over 30 years in Ontario. Nancy has extensive experience in managing financial processes, risk, policy, and governance as a staff and board member in not-for-profit and charitable organizations. In July 2021, Nancy retired from her position as Executive Director, Financial Affairs, at McMaster University. Nancy is proud of her work in leading the Hamilton Myeloma March since 2018, and especially proud that their September 2020 Zoom/in-person March raised over $53,000. Nancy’s husband has been living with myeloma since 2017.
Trevor Ives, Director
Trevor Ives is a chartered accountant with over 25 years of experience in Aboriginal Business and Corporate Development. As CEO for the Peter Ballantyne Group of Companies, Trevor has developed a diversified business base for First Nations in the manufacturing, retail, service, property development and forestry industries. He has led business expansion and development through a series of green field developments, acquisitions, and partnerships. Trevor is active on many corporate Boards and within local organizations in his community, using his expertise to help guide them to success. Trevor lives in Prince Albert, SK with his wife Shauna and their 2 children. He was diagnosed with myeloma in 2019.
Bill Paine, Director
Bill Paine holds an MBA and has over 30 years of experience as a senior executive and board member with Canadian public companies in the energy industry, and has also held board and senior management roles within community and national charitable organizations. His expertise includes building businesses in more than 20 countries. Bill currently serves on the boards of a TSX- listed Canadian energy company, and two international energy companies. He previously focused on fundraising from corporate, community and governmental sources for a not-for-profit in Vancouver. Bill’s been actively involved with Myeloma Canada in corporate fundraising, community support groups, and the Myeloma PSP Steering Committee. He and his wife, who has myeloma, are enjoying full and productive lives in Vancouver with their new puppy, Cooper.